Early detection of anti‐drug antibodies during initiation of anti‐tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease
Quentin Tournier, Stephane Paul, Nicolas Williet, Anne‐Emmanuelle Berger, Pauline Veyrard, Gilles Boschetti, Bertrand Le Roy, Martin Killian, Jean Marc Phelip, Bernard Flourie, Stephane Nancey, Xavier Roblin- Pharmacology (medical)
- Gastroenterology
- Hepatology
Summary
Background
Anti‐drug antibodies develop mostly during the induction therapy with anti‐tumour necrosis factor (TNF) drugs and can be revealed by means of a drug‐tolerant assay.
Aim
To investigate whether the early detection of anti‐drug antibodies during the induction therapy was predictive of treatment discontinuation.
Methods
In a prospective study, consecutive patients with inflammatory bowel disease (IBD), who should start an anti‐TNF, were enrolled and followed regularly during 24 months or less in case of non‐ or loss of response (LOR) or adverse events requiring treatment discontinuation. Anti‐TNF levels and anti‐drug antibodies were measured at week 2 for adalimumab (ADA) and weeks 2 and 6 for infliximab (IFX) using a drug‐tolerant assay.
Results
One hundred and eight patients were enrolled (54 under ADA). At week 2, antibodies to ADA and to IFX were detected in 76% and 67% of patients. Time to treatment discontinuation was significantly shorter (P < 0.001) in patients with antibodies to ADA ≥2.0 µg/mL‐eq (6.0 vs 24 months, HR = 18.51, 95% CI [4.35‐78.71]) or with antibodies to IFX ≥4.0 µg/mL‐eq (5.5 vs >24 months, HR = 13.89, 95% CI [4.08‐47.31]) at week 2 compared to patients without positive antibodies. Antibodies to ADA and to IFX were predictive of treatment failure within 24 months with a sensitivity of 79% and 62%, and specificities and positive predictive values of 100%. In multivariate analysis, antibodies to ADA or to IFX at week 2 were the only factors associated with treatment discontinuation.
Conclusions
The prevalence of antibodies to anti‐TNF is high when detected early using a drug‐tolerant assay, and their appearance predicts further treatment discontinuation.